Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Phase 3HLP003Positive

AI Analysis

Summary

Helus Pharma completed enrollment in the Phase 3 APPROACH study of HLP003 for adjunctive treatment of major depressive disorder ahead of schedule, with topline data expected in Q4 2026. The company continues enrollment in the EMBRACE study and participant rollover into the EXTEND long-term safety study.

Clinical Trial Data

Phase

Phase 3

Outcome Details

APPROACH study enrollment completed ahead of schedule; EMBRACE study enrollment ongoing; topline data readout on track for Q4 2026

Importance:7/10

Sentiment:

0.70

Phase 3enrollment completeahead of scheduledepressionPARADIGM program

Read the original article

Published by PR Newswire Biotech on July 21, 2026 2:54 PM

Read Original